Compare CSGP & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSGP | RDY |
|---|---|---|
| Founded | 1987 | 1984 |
| Country | United States | India |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.4B | 11.8B |
| IPO Year | 1998 | 2001 |
| Metric | CSGP | RDY |
|---|---|---|
| Price | $29.63 | $12.63 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 1 |
| Target Price | ★ $60.57 | $16.90 |
| AVG Volume (30 Days) | ★ 6.9M | 3.0M |
| Earning Date | 04-28-2026 | 05-12-2026 |
| Dividend Yield | N/A | ★ 0.52% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $965,230,000.00 | N/A |
| Revenue This Year | $19.71 | $7.72 |
| Revenue Next Year | $12.40 | $3.50 |
| P/E Ratio | $3,047.50 | ★ $18.67 |
| Revenue Growth | ★ 15.23 | N/A |
| 52 Week Low | $26.68 | $12.19 |
| 52 Week High | $97.43 | $15.67 |
| Indicator | CSGP | RDY |
|---|---|---|
| Relative Strength Index (RSI) | 47.63 | 34.89 |
| Support Level | $28.18 | $12.19 |
| Resistance Level | $34.84 | $13.96 |
| Average True Range (ATR) | 1.26 | 0.37 |
| MACD | 0.22 | -0.22 |
| Stochastic Oscillator | 68.79 | 2.35 |
CoStar Group is a global provider of proprietary information, analytics, and online marketplaces serving both commercial and residential real estate. The firm operates through a diverse portfolio of brands, including CoStar Suite for commercial real estate research, LoopNet for commercial listings, Apartments.com for multifamily rentals, and Homes.com for residential brokerage. It primarily sells high-margin software-as-a-service subscriptions that provide institutional clients with forensic property data and premium advertising visibility. With operations across North America, Europe, and Asia-Pacific, CoStar maintains the industry's most comprehensive centralized real estate database, functioning as a critical information utility for brokers, lenders, and owners worldwide.
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly 40% of its generics sales, with other key markets being India (20%) and Europe (20%). Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.